Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
MicroRNAs in the development of potential therapeutic targets against COVID-19: A narrative review

Jivan Qasim Ahmed, Sazan Qadir Maulud, Manish Dhillon, Priyanka, Om Prakash Choudhary, Paywast Jamal Jalal, Rezna Kheder Ali, Gahin Abdulraheem Tayib, Dhishad Abdullah Hasan

Department of Pathology and Microbiology, University of Duhok, Kurdistan Region, Iraq
Department of Biology, College of Education, Salahaddin University-Erbil, Kurdistan Region, Iraq
Department of Microbiology, Punjab Agriculture University, Ludhiana, 144004 Punjab, India
Trafalgar College, Altrincham, Manchester, WA14 5PQ, UK
Department of Veterinary Microbiology, College of Veterinary Science, Guru Angad Dev Veterinary and Animal Sciences University (GADVASU), Rampura Phul, Bathinda 151103, Punjab, India
Department of Veterinary Anatomy and Histology, College of Veterinary Sciences and Animal Husbandry, Central Agricultural University (I), Selesih, Aizawl, 796015, Mizoram, India
Department of Biology, College of Science, University of Sulaimani, Kurdistan Region, Iraq
Public Health Laboratory Management-Erbil, Kurdistan Region, Iraq

Article history:
Received 24 February 2022
Received in revised form 16 June 2022
Accepted 19 June 2022

Keywords:
COVID-19
SARS-CoV-2
ACE2 receptor
MicroRNA
Therapeutics

Background: As the therapeutic regimens against the COVID-19 remain scarce, the microRNAs (miRNAs) can be exploited to generate efficient therapeutic targets. The miRNAs have been found to play pivotal roles in the several regulatory functions influencing the prognosis of viral infection. The miRNAs have a prospective role in the up and down regulation of the ACE2 receptors. This review examines the clinical applications, as well as the possible threats associated with the use of miRNAs to combat the deleterious consequences of SARS-CoV-2 infection.

Methodology: This article was compiled to evaluate how the miRNAs are involved in the SARS-CoV-2 pathogenesis and infection, and their potential functions which could help in the development of therapeutic targets against the COVID-19. The sources of the collected information include the several journals, databases and scientific search engines such as the Google scholar, PubMed, Science direct, official website of WHO, among the other sites. The investigations on the online platform were conducted using the keywords miRNA biogenesis, miRNA and ACE2 interaction, therapeutic role of miRNAs against SARS-CoV-2 and miRNA therapy side effects.

Results: This review has highlighted that the miRNAs can be exploited to generate potential therapeutic targets against the COVID-19. Changes in the miRNA levels following viral replication are an essential component of the host response to infection. The collection and modification of miRNA modulates may help to minimize the deleterious consequences of SARS-CoV-2 infection, such as by controlling or inhibiting the generation of cytokines and chemokines. The degradation of viral RNA by the cellular miRNAs, along with the reduced expression of ACE2 receptors, can substantially reduce the viral load. Specific miRNAs have been found to have an antiviral influence, allowing the immune system to combat the infection or forcing the virus into a latency stage.

Conclusion: This review summarizes several studies revealing the involvement of miRNAs in diverse and complex processes during the infection process of SARS-CoV-2. The miRNAs can substantially reduce the viral load by degradation of viral RNA and reduced expression of ACE2 receptors, besides mitigating the deleterious consequences of the exaggerated secretion of cytokines. Extensive investigations need to be done by the scientific community to utilize the miRNA based strategies for the development of effective therapeutic targets against the COVID-19.

© 2022 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the new coronavirus disease 2019 (COVID-19), which belongs to the group of beta coronaviruses in the Coronaviridae family [1], which has the closest relationship and likelihood with the previously emerged SARS-CoV in 2003 that was known by SARS outbreak [2,3]. Human coronaviruses (HCoVs) infections usually target upper and lower respiratory tract infections. Some of the human coronaviruses like a human coronavirus NL63 (HCoV-NL63), human coronavirus OC43 (HCoV-OC43), and human coronavirus HKU1 (HCoV-HKU1), comes as minor infection and lead to common colds [2]. Moreover, during the last two decades, a group of highly infectious coronaviruses with a severe infection in the human population have been characterized, comprising severe acute respiratory syndrome coronavirus (SARS-CoV), that resulted in an outbreak in the year 2003 and infected more than 8000 people globally with a mortality rate of around 10 %. Middle East respiratory syndrome coronavirus (MERS-CoV) appeared in the year 2012 and infected around 2500 people with a fatality rate of around 37 % [4]. Several studies have revealed that such a highly pathogenic coronavirus resulted in severe and acute respiratory distress syndrome (ARDS), resulting in diffused inflammation in the respiratory system, difficulty in breathing, and even death. In contrast, SARS-CoV-2 has a tendency to spread more rapidly than SARS-CoV and MERS; however, the fatality rate tends to be lower than 2–3 % in comparison [5,6].

The COVID-19 pandemic has resulted in 516 million cases with a fatality of 6.2 million people worldwide, as well as posing significant problems to healthcare facilities and medical infrastructure [7,8]. This situation has sparkled widespread alarm, as well as threats and financial losses all around the world [7]. Furthermore, because COVID-19 is a unique virus, the US Food and Drug Administration (FDA) has not approved any specific treatments for it, necessitating some perturbations in the miRNA's synthetic pathway and their biological function. The immune response is vital for controlling and resolving SARS-CoV-2 infections, but it can also cause cellular damage, which is linked to an aggravated immunological response [11,12]. MicroRNAs (miRNAs) were discovered to play a key part in the intricate network of interactions between the eukaryotic agent and infected host cells [11–13]. A cytokine storm-generated during viral infection, particularly in the case of SARS-CoV-2, has been found to result in an overactive immunological response that is significantly harmful to host cells [12–14]. Recent data has suggested that the collection of miRNAs modulates each of these stages, and these miRNAs can be exploited to generate therapeutic targets for the reliable and efficient treatment of patients with COVID-19 [15]. As a result, manipulating miRNAs may help to minimize COVID-19’s pathogenicity and reduce the deleterious consequences of SARS-CoV-2 infection [9], such as by controlling or inhibiting the generation of cytokines and the chemokines. Among several nucleic acid-based therapeutic approaches, miRNAs have been postulated as one of the promising therapeutic strategies to combat COVID-19 [15,16].

MicroRNAs (miRNA) are non-coding RNAs, small molecules with nucleotides length of around 17–25 [17]. miRNAs at most are produced by transcription from DNA template to produce primary miRNAs and subsequently go under process to produce precursor miRNAs, and mature miRNAs produce precursor miRNAs and mature miRNAs. Mainly, miRNAs anneal to the 3′ UTR of target messenger RNAs (mRNA) [18] and are significant regulators of the gene expression process at the post-transcriptional level. miRNAs play a decisive function in different biological phenomena, including cell propagation, differentiation, growth, and apoptosis [19]. Nevertheless, it has been revealed that miRNAs can achieve additional positions on the mRNA, comprising the 5′ UTR, gene promoters, and coding sequence [20]. Additionally, miRNAs have been reported to trigger gene expression in some circumstances [21]. Researchers have proposed that miRNAs play a crucial role in controlling the transcription and translation rate through moving between various subcellular compartments [22]. Lee and his colleagues in 1993, discovered miRNAs for the first time. They have found that they have a role in the down-regulation of an essential protein called LIN-14, responsible for developing the Caenorhabditis elegans nematode larvae from the L1 stage to the L2 stage [23]. The miRNA biogenesis is an active process that consists of many steps that lastly lead to the production of mature miRNAs [24]. Due to the complexity of the miRNA’s transcription, maturation, and functioning, any disruption in these processes can interrupt the miRNA synthesis pathway and biological activities, which may severely decrease or increase miRNA production in a particular tissue. The perturbations in the miRNA’s synthetic pathway and their biological activities can lead to a poor prognosis of the diseases, especially in the case of SARS-CoV-2 infection [25,26].

Numerous studies have found that miRNAs play a significant role in the interaction of viruses and host cells. Despite the fact that the role of host miRNAs in SARS-CoV-2 infection has been predicted, experimental data are still lacking [26]. Furthermore, clinical trials have yet to demonstrate that antiviral miRNAs can be used to modulate the host immune response to SARS-CoV-2 infection. The genomic difference that, as a result, controls the host miRNA target sites and viral miRNAs might explain the difference between SARS-CoV and various isolated SARS-CoV-2 in terms of pathogenesis and infectivity [27]. Therefore, seeking new biological strategies for treating viral diseases is highly recommended. It is essential to...
notice that the previous along with recent shreds of the data imply that miRNAs can play important functions in modulating the immune system toward respiratory viruses, such as Human coronaviruses (HCoVs) that includes SARS-CoV-1, MERS, SARS-CoV-2, and other types of HCoVs, human metapneumovirus (hMPV), human rhinovirus (hRV), IV, and RSV. Also, changes in the expression of miRNAs in epithelial cells may participate in the pathogenesis of both severe and chronic respiratory infections [9,28]. Although underappreciated, miRNAs expressed in human lung cells may also be an important factor in determining COVID-19’s severity [29]. Hence, modulation of miRNAs might mitigate COVID-19 pathological negative effects and decrease host damage.

In addition, the role of miRNAs in the infectivity of coronaviruses has not been examined in-vivo studies [30]. Furthermore, it has been demonstrated that high-dose single miRNA administration is required to obtain the best therapeutic efficiency and reliability, but the administration of the high dose of single-miRNA can have negative consequences. As a result, a cocktail of miRNAs may have fewer off-target effects and be more effective than monotherapy [31,32]. The production of miRNAs and their significance in the control of the host immune response are the subjects of this review. The clinical application of miRNAs, as well as the possible threats connected with their use, is also highlighted in this review.

**Genomic architecture of SARS-CoV-2**

SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA [33], and its genetic material is the largest of all RNA viruses [34]. SARS-CoV-2 genome size is around 30 kb and is translated into a total of 29 proteins of functional and viral structural proteins. Over two-thirds of the genome of SARS-CoV-2 is composed of orf1ab at the 5’ end of the sequence, which encodes orf1ab polyproteins. In contrast, the rest of the genome contains the structural protein encoded genes which are spike protein (S), an envelope protein (E), membrane protein (M), and nucleocapsid protein (N) at the downstream of the viral genome. Furthermore, the genome of SARS-CoV-2 has six more genes that include “ORF3a, ORF6, ORF7a, ORF7b, and ORF8 genes” that code for six additional proteins [35,36]. The structural and genomic organization of SARS-CoV-2 has been demonstrated in Fig. 1.

**Biogenesis of miRNAs**

MicroRNAs (miRNAs) are highly conserved, small (about 22 bp long), non-coding single-stranded ribonucleic acids (RNAs) that control the expression of complementary messenger RNAs (mRNAs). They repress the translation of target mRNA by binding to the 3’ ends in the untranslated regions (UTRs) or to a specific region in open reading frames (ORFs) of mRNA transcription [34]. In humans and other eukaryotic species, miRNA biogenesis occurs in two stages, with nuclear and cytoplasmic cleavage events [38,39].

**Transcription of miRNA in the nucleus**

The biogenesis mechanism of miRNA starts in the nucleus through the transcription from genes encoding for miRNA through RNA polymerase II, or RNA polymerase III, leading to the formation of a primary transcript that encodes miRNA called pri-miRNAs of a hairpin structure of about 1000 nucleotides (nt) long [37]. This stage is negatively or positively controlled through RNA polymerase II-associated transcription factors, including ZEB1, ZEB2, MYC, and p53, as well as epigenetic modulators like the DNA methylation and modification of histones [40]. RNA pol II is considered to be accountable for most of miRNA’s transcription between two RNA pol enzymes, RNA pol II and RNA pol III (Fig. 2). The size of pri-miRNA, which is usually more than 1 kb lengthy than the pol III transcripts, demonstrates the priority for RNA pol II. In addition, pri-miRNA contains uridine residue sequences that stop pol III transcriptions [39]. These snippets of information bolster the idea that RNA pol II is involved in the transcription of most of the pri-miRNAs. Nevertheless, it is important to note that RNA pol III is involved in the transcription of certain miRNAs, such as miR-142 [41]. In addition to the aforementioned characteristics, transcriptional start locations are positioned far from the genes, and promoters comprise RNA pol II-specific features [39–42]. The transcriptional control of miRNAs can sometimes be described as a feedback loop in which positive or negative regulations of miRNA can decrease or amplify their own transcription [39–43]. Around half of the recognized miRNAs are intragenic and commonly transcribed from introns (non-protein coding genes). In contrast, transcription from exons (protein-coding genes) is moderately limited. These transcription processes are independent of their host genes and are controlled through their own specific promoters [44]. Sometimes, miRNAs transcription comes as a single extended sequence known as miRNAs clusters. This can have a related target position; hence they are considered as family miRNAs [45].

**Genesis of pre-miRNA in the nucleus**

Following the miRNA transcription genes through RNA polymerase II in the nucleus, the primary miRNA undergoes several maturation cycles. The first-ever step of primary miRNA processing occurs in the nucleus, and the Ribonuclease III (RNase III) Drosha, alongside the help of DGCR8 (DiGeorge syndrome critical region gene 8) co-factor, produces the Microprocessor complex that cleaves the primary miRNA loop end, resulting in the formation of precursor miRNA, named pre-miRNAs that has a hairpin structure of about 70 nucleotides (nt) long [46] (Fig. 2). Furthermore, pri-miRNA transforms into an operational miRNA with a flexible terminal loop of approximately ten bp and 5’ phosphate, as well as two nt (nucleotide) 3’ ssRNA (single-stranded RNA) overhangs. Drosha, an RNase III endonuclease, and the dsRNA (double-stranded RNA)-binding protein DGC8R, also known as pasha, are involved [38–47]. The pre-miRNA features a staggered cut with a 5’ phosphate and 3’ overhang of 2 nt [47].

**Maturation of pri-miRNAs into the mature miRNAs in the cytoplasm**

The produced precursor miRNAs are transported into the cytoplasm through Exportin-5 to go through the subsequent stages of maturation [48]. Here, precursor miRNAs are cleaved again by an enzyme called Dicer, a cytoplasmic RNase endonuclease, to form mature duplex miRNAs of around 22 nt long [49,50]. Furthermore, the produced miRNAs duplex, along with the protein named argonaute (AGO), further produces the miRNA-induced silencing complex (miRISC) [50]. The miRNA biosynthesis reveals the processes that control the expression of its target gene shown in Fig. 2 (Fig. 2). Regulation of genes and intercellular signaling is the main significant function played by miRNAs [18]. In terms of gene regulations, the formed miRISC can function through two pathways called canonical and non-canonical pathways [51]. In the canonical pathway, miRISC anneals to the 3’ UTR of the targeted mRNA, resulting in the translation termination process when both strands are exactly complementary to each other, or leading to a reduction in both strands are exactly complementary to each other or reducing translation during limited complementarity between two strands [52]. In contrast, complete complementarity is not required by the non-canonical pathway [53]. One miRNA may regulate many miRNAs, but also, one miRNA may be regulated by several miRNAs [54].

Recent studies have shown miRNAs play pivotal roles in several regulatory functions which decide the prognosis of the infection, especially in viral infections. Generally, its known that viruses are
obligate intracellular pathogens whereby only count on the targeted cell for replication and infection [13]. Viruses are known to have the capability to upregulate or downregulate key miRNAs of the host to gain the ability to evade the host’s immune response [55]. Conversely, specific miRNAs were discovered to have an antiviral influence, allowing the immune system to combat the infection or forcing the virus into a latency status [56]. Keeping all the above points in mind, we summarise how miRNAs are involved in SARS-CoV-2 pathogenesis and infection processes, and the potential functions they provide might help find and develop an antiviral therapeutic agent for many viral infections that do not have a complete cure in the meantime.

**Therapeutic potential of miRNAs against SARS-CoV-2**

Viruses replicate their genetic material by using the host’s cellular machinery. During this process, interactions can occur between host miRNAs and the viral genome. These interactions can occur via three pathways: mRNA blocking, mRNA destabilization, and mRNA degradation via protein complexes [57]. In addition to the host miRNAs, some viruses can generate their miRNAs [58]. The miRNAs of the virus take part in the replication cycle in the infected host cell and might result in some alterations in the infected cell [59] (Fig. 3). Concerning the role, the host miRNAs are categorized as proviral or antiviral depending on the actions during a certain viral infection. The interaction between the host and viral miRNAs might allow the virus to replicate in the host cell and extend the infection to other cells, consequently bringing about proviral roles [60]. Additionally, proviral miRNAs can allow a viral infection through antiviral factors suppression like interferons (IFNs), letting the virus do an immune evasion of the host immune system [61].

There are different ways against the SARS-CoV-2 infection: inhibiting the viral replication, blocking cellular receptors, and obstructing the function of viral proteins [62]. The cellular miRNA expression has an important impact on the regulation of viral replication by T lymphocyte involvement and response of defense mechanisms to viral infections [63]. miRNAs can inhibit the viral translation after the attachment of miRNAs to 3’-UTR of the viral genome or target the receptors, structural or non-structural proteins of SARS-CoV-2 without affecting the expression of human genes [64]. Balmeh et al. downloaded the nucleotide sequences of 1872 miRNAs from the miRBase database. Forty-two miRNAs had the highest score, which mitigates the pathogenesis of COVID-19 disease via binding to the SARS-CoV-2 genome and inhibiting its post-transcriptional expression [65]. Chan et al. reported that mutations in SARS-CoV-2 3’-UTR lead to virus escape from the host immune system [66].

In the case of infection, the non-coding SARS-CoV-2 miRNA may interfere with normal cellular homeostasis by upregulating certain host mRNA levels generally controlled by the host miRNAs. Consequently, by down-regulating specific host miRNAs, the virus enhances its replication cycle and attenuates the host’s immune...

*Fig. 1. Structural organization of SARS-CoV-2 genome and viral induced miRNA.*
responses [67]. Bioinformatics analysis of the SARS-CoV-2 genome reveals potential miRNAs’ binding sites in various genome regions, e.g., in the critical 5’ UTR regions of ACE-2 (angiotensin-converting enzyme-2) or TMPRSS2 (transmembrane protease serine 2) [68]. On the other hand, viral miRNAs can also affect the expression of host mRNAs. They are involved in cell proliferation and survival, stress responses, and antiviral responses such as Toll-like receptors (TLRs) or cytokines such as type I IFN.

Upon entry into the host cell, SARS-CoV-2 releases its genomic RNA. Consequently, the host antiviral immune responses are attenuated. Alternatively, viral miRNAs can reduce virus replication in infected cells, allowing the host cells to survive, go into a latency state, and increase viral spread to other people in the population [69]. Some viral miRNAs target specific host mRNAs and miRNAs, thereby altering gene expression and modulating the pathways associated with the immune system. At the same time, host cells may change their own miRNA expression profile to defend themselves against the disease [70]. Therefore, miRNA will provide a practical concept to elucidate the infectivity and replication process of the current SARS-CoV-2 pandemic. Whereas SARS-CoV closely resembles SARS-CoV-2, many interactions have been established in their sign appearances presented by them. However, there are marked differences between diseases caused by both viruses [71]. An overview of the role of the SARS-CoV-2-miRNA on the host immune system activity that has been explored is shown in Table 1.

A study conducted by Mallick et al. in 2009 assessed the miRNA landscape in human bronchoalveolar stem cells (BASCs) was assessed at the time of infection with SARS-CoV, displaying the up-

![Fig. 2. miRNA biogenesis and post-transcriptional regulation of genes.](image)

![Fig. 3. Diagrammatic representation of the role of both cellular and viral miRNAs.](image)
regulation of miR-17, miR-214, and miR-574–5p, that results in viral replication inhibition, and consequently, evasion of immune response before the virus has been successfully transmitted, in addition to the down-regulation of miR-98 and miR-223 to control the BASCs differentiation, proinflammatory cytokine activation and suppression of ACE2. It was also observed that S and N proteins in BASC down-regulate both miR-98 and miR-223 to influence many stages of the maturation process in these cells and enable inflammation-related cytokines to reduce the function of the ACE2 enzyme. Such a mechanism essentially forms the productive transmission and replication of viruses inside BASC, resulting in continuous degradation of cells of the respiratory tract and consequently damaging the repairing ability [72]. In general, this study revealed the various ways in which a virus utilizes cellular miRNA instruments to its advantage. Hosseini et al. have recently identified seven targets for miRNA in the SARS-CoV-2 genomic RNA. There were initially ten goals, but three of them were lost because of mutations that had been retained. "MiR-574–5p, miR-214, miR-17, miR-98, miR-223, and miR-148a" are those host miRNAs that are capable of annealing to encoding transcripts of the SARS-CoV-2; consequently, resulting in immune system mediation [73].

In addition, an in-silico study conducted by Fulzele et al. has identified around 873 miRNAs in the host targeting the SARS-CoV-2 strain, of which around 558 also target genomic genes in the SARS-CoV. Further illustrating that the miRNAs that have the top score of targeting the sequence are thus commonly expected to have definite target positions on the SARS-CoV-2 genomic RNA were "miR-15a-5p, miR-15b-5p, miR-30b-5p, miR-409–3p, miR-505–3p, and miR-548d-5p", according to their report [74]. These cellular miRNAs indicate potential antiviral activity on both SARS-CoV and SARS-CoV-2 viruses. Therefore, testing these miRNA in-vitro and in-vivo animal models would be essential for possible usage as a target as a therapy. Importantly, a recent study found that the number of circulating miRNAs from several tissues, including numerous established cardiometabolic indicators, increases with COVID-19 severity. MyomiR miR-133a and liver-derived miR-122 have been linked to 28-day mortality. MiR-133a is associated with inflammation-induced myocyte damage, whereas miR-122 is associated with the hepatic acute phase response. It has been suggested that future research is needed to determine whether miR-133a or miR-122 measurements have the potential to help in prognosis estimation by assessing organ damage and inflammation resolution, which might affect treatment decisions. As a result, it is intriguing to examine whether miRNA analysis during SARS-CoV-2 infection might be used as a diagnostic biomarker to predict illness severity. This can be used to offer the host with tailored therapy [75].

In coronavirus infection, cocktails of several miRNAs mimicking the intra nasal route would be beneficial. These human miRNAs efficacy against coronaviruses may help prevent any potential outbreaks. In an earlier analysis, cellular miRNAs-181 of the host bind to the ORF-4 region of the porcine reproductive and respiratory syndrome virus (PRRSV) viral genome to prevent replication of the virus. Furthermore, Guo et al. administered miR-181 mimics through intranasal inoculation to reduce the lethal effect of PRRSV on piglets [77]. Likewise, the intranasal inoculation of five miRNA mimics is chemically modified to protect against H1N1 replication in mice [78]. The role of cellular miRNA has been described in Table 2.

The binding position for miRNA predicted through the Computational approaches should be considered cautiously, as findings frequently were unsuccessful for experimental verifications. Such an increased false-positive number of the predicted site for the miRNA target has often been mentioned. However, specific methods, like multi-targeting, incorporation of current experimental data, or the usage of algorithms considered for refining the effects of miRNA target hunts [79], may be used to narrow it down. Conditions unique to the research question may also be helpful to consider ("e.g., excluding potential targets of all miRNAs that are not expressed in cells prone to SARS-CoV-2 infection").

Based on the Hosseini et al. studies [73] and Fulzele et al., such steps have been taken to refine the findings. Nevertheless, their results remain encouraging and must be considered for additional

### Table 1

| miRNAs        | Related process                                      | Reference |
|---------------|------------------------------------------------------|-----------|
| miR147-3p     | enhanced the expression of TPRSS2                    | [81]      |
| MR385-3p      | Regulate T-cell activation and survival              | [9]       |
| MD2–5p        | reducing the host cell apoptotic, evasion immune system |          |
| MR133a        |                                                    | [82]      |
| MD241–3p      | Pulmonary vasculature                                |          |
| MD3–1p        | Antiviral innate immunity, an inducer of apoptosis pathway during viral infection |          |
| mir-D8–5p     | enhance viral replication, host cell survival and host immune evasion |          |
| mir-R1–5p     | Evasion immune system                                | [83]      |
| miR-D6–3p     |                                                    |           |
| miR-D10–5p    |                                                    |           |
| miR-D5–3p     |                                                    |           |
| miR-D11–5p    |                                                    |           |
| miR-D14–3p    |                                                    |           |
| miR-D2–3p     |                                                    |           |
| miR-R3–3p     |                                                    |           |
| miR-R5–5p     |                                                    |           |
| miR-R6        |                                                    |           |
| miR-R4        |                                                    |           |
| miR-R2        |                                                    |           |
| miR-D13       |                                                    |           |
| miR-D12       |                                                    |           |
| miR-D9        |                                                    |           |
| miR-D7        |                                                    |           |
| miR-D4        |                                                    |           |
| miR-D3        |                                                    |           |
| miR-D1        |                                                    |           |

**Note:** The table lists miRNAs and their related processes, along with references for their study and function. The process descriptions cover various aspects of the virus-host interaction, including immune response, viral replication, and cellular damage.
An overview of the role of the cellular-miRNA on the SARS-CoV-2 activity has been explored.

| Cellular-miRNA | Related process | Reference |
|----------------|-----------------|-----------|
| miR-17, miR-214, miR-574–5p | Viral replication inhibition, evasion of immune response | [72] |
| miR-98, miR-223 | bronchoalveolar stem cells differentiation, proinflammatory cytokine activation, suppression of ACE2, immune system mediation | |
| miR-98, miR-223, miR-148a | bronchoalveolar stem cells differentiation, proinflammatory cytokine activation, suppression of ACE2, immune system mediation | |
| miR-15a-5p, miR-15b-5p, miR-30b-5p, miR-409–3p, miR-505–3p, miR-548d-3p | antiviral activity | [74] |
| miR-181, miR-130 | inhibit replication | [76] |
| miR-200, miR-429, miR-200b, miR-200c | reduce the lethal effect of PRRSV | [77] |
| miR-155, miR-9 | suppression in ACE2 expression, lowering the ACE2-facilitated infection | [84] |
| miR-6864–5p, miR-5197–3p, miR-4778–3p, miR-538b-5p, miR-32 | mitigate the pathogenesis, inhibit its post-transcriptional expression | [87] |
| miRNA-3154, miRNA-7114–5p, miRNA-5197–3p, miR-5197–3p, miR-17–5p, | Viral replication inhibition block the assembly and production of viral particles evasion of immune response | |
| miR-18 | suppression in ACE2 expression | [88] |
| miR-146a | Regulate Toll-like receptors (TLRs) downstream signalling, regulate innate immune response block viral RNA replication | [89] [90] |
| miR-4288, miR-6838–5p, miR-497–5p, miR-510–3p, miR-624–5p, miR-31–5p, miR-423–5p, miR-23a–3p, miR-42a-5p, miR-29b-3p, miR-338–3p, miR-4661–3p, miR-4761–5p, miR-4793–5p, miR-8066, miR-190a–5p | Viral replication inhibition antiviral activity | [91] [92] |
| miR-26a-5p, miR-29b-3p, miR-34a-5p, miR-6501–5p, miR-618, miR-183–5p, miR-627–5p, miR-144–3p | regulate the immune responses, Viral replication inhibition | [93] |
| miR-1–3p, miR-199a-1p, miR-20a-5p, miR-4661–3p, miR126–3p, miR-198, miR-622 | T-cell differentiation and activation, Viral replication inhibition, evasion of the immune system | [94] |
| | antiviral activity regulating inflammation | [81,87] [95] |
| | Antiviral activity inhibit viral replication | [27] |
studies on pathogenesis and possible miRNA therapy for Covid-19 [74]. Host and viral miRNA’s biosynthesis and the role of miRNA in the host during COVID-19 infection has been illustrated (Fig. 3).

The suppressive of the SARS-CoV-2–encode miRNAs on these genes suggested that the possible role of the SARS-CoV-2–encode miRNAs on these genes suggested their potential role in reducing the host cell apoptotic to subvert host defense. Therefore, we also searched the targets of SARS-CoV-2 encoded miRNA on the 5′-UTR of human genes. The 11 virus miRNAs were identified to bind to the 5′-UTR of 13 target genes, including the binding between MR385–3p and TGFBR3 (Transforming Growth Factor Beta Receptor 3), a widely recognized gene expressed in cells of both the innate and adaptive immune system. It is reported to play a role in promoting Th1 differentiation and regulation of regulatory T-cell activation and survival. MR147–3p targets the enhancer of TMPRSS2 in the gut. Several studies have implicated the gastrointestinal infection of SARS-CoV-2 [9]. Fig. 4.

Furthermore, in recent research, the plasma miRNAs and cytokines profiles of COVID-19 and other community-acquired pneumonia (CAP) were compared. A preliminary screening and subsequent validation tests in a separate cohort of patients identified a pattern of 15 dysfunctional or dysregulated miRNAs in COVID-19 and CAP patients. Furthermore, multivariate analysis revealed that the conjunction of four miRNAs, namely, miR-106b-5p, miR-221–3p, miR-25–3p, and miR-30a-5p, substantially differentiated between the two disorders. The search for miRNA targets, along with plasma protein measurements, revealed a distinct cytokine signature between COVID-19 and CAP, which comprised EGFR, CXCL12, and IL-10. There were also significant changes in plasma levels of CXCL12, IL-17, TIMP-2, and IL-21R between mild and severe COVID-19 individuals. These findings shed light on the etiopathological pathways that characterize COVID-19. It is worth noting that the differential expression of suggestive miRNAs, in conjunction with specific cytokines, can determine the severity of COVID-19 illness [80]. As a result, miRNAs can not only be utilized as therapeutic regimens but also be used as reliable diagnostic indicators.

**miRNAs and ACE2 receptor expression in SARS-CoV-2 infection**

ACE2 is known to aid in maintaining blood pressure and the balance of electrolytes in the body. Similarly, it also lowers the amount of circulating Angiotensin II through suppression of the renin-angiotensin-aldosterone system with the activity of anti-hypertension. Lately, ACE2 has been identified as a target receptor for the spike protein of SARS-CoV-2 and shows essential roles throughout the COVID-19 infection [96]. Notably, many other medical conditions, like cardiovascular system diseases, diabetes, and asthma, also tend to affect COVID-19 patients with severe symptoms [84]. It is important to remember that ACE2 is expressed in cardiomyocytes, and the expression level is increased in hosts suffering from heart illnesses. Therefore, the level of SARS-CoV-2 infection may become the level of SARS-CoV-2 infection may become further prominent through ACE2 in patients with comorbidities, which sequentially might lead to further myocardial harm. Some studies have stated that miRNAs might potentially control ACE2 expression in many types of cells and under disease circumstances. However, there is still a scarcity of clinical trials to provide a vivid image of miRNAs’ potential to develop effective and reliable therapeutic regimens against COVID-19 [26–97]. ACE2-associated miRNAs, in particular, should be carefully explored since ACE2 is the essential factor that requires more focus owing to its association with the viral agent, which can be SARS-CoV or SARS-CoV-2 [98,99]. As a result, it has been suggested that the clinical manifestations of certain ACE2-associated miRNAs, such as miR-18, miR-29, and miR-125b, be thoroughly investigated in order to find novel miRNA-based therapies for COVID-19; specifically, it is presumed that the use of anti-miR-18

Fig. 4. The host and viral miRNA’s biosynthesis and the role of miRNA in the host due to COVID-19 infection.
and anti-miR-125b may be beneficial in treating COVID-19-related nephropathy [88,100].

The miR-200 is considered a family of several miRNAs that also include miR-421, miR-200b, and miR-200c. These are well-recognized mirNA families that are highly studied in anti-cancer research [30]. Similarly, it has been revealed that the miR-200c level is up-regulated in cardiovascular diseases [101]. In a study performed by Lu et al. to investigate the mirR-200c Role in SARS-CoV-2, it was found that increased expression of miR-200c induced suppression in ACE2 expression in both human and rat's cardiomyocytes. Moreover, there has suggested more investigation to study the possible miR-200c role in lowering the ACE2-facilitated infection of human-induced pluripotent stem cell-derived cardiomyocytes by SARS-CoV-2 or SARS-CoV-2 spike pseudotype viruses are acceptable. Nevertheless, bearing in mind that the association of miR-200c and cardiovascular diseases, together with the up-regulation of miR-200c, must be cautiously examined [30].

In a recent study, researchers looked at the blood levels of soluble ACE2 (sACE2) and four microRNAs (miR-421, miR-3909, miR-212–5p, and miR-4677–3p) in COVID-19 patients and compared them to clinical and pathological variables [101]. Irrespective of gender, diabetes condition, or obesity, sACE2 levels were elevated in COVID-19 individuals. Additionally, the four miRNAs studied were elevated in COVID-19 patients and were found to be positively associated. Likewise, sACE2 was strongly related to miR-421, miR-3909, and miR-4677–3p, indicating a significant relationship between these markers. MiR-212–5p was shown to be increased exclusively in moderately infected patients. Additionally, it has been found as unique in the case of male and non-obese COVID-19 patients. MiR-212–5p was shown to be connected with d-dimer, which has an important prognostic marker in severely infected COVID-19 patients. Whereas sACE2 was found to be positively correlated with coagulation tests such as aPTT and platelets, showing their usefulness as coagulopathy indicators in patients with COVID-19. In diabetic COVID-19 patients, there was also a significant connection between sACE2 and C-reactive protein (CRP), suggesting that this marker may have a role in their inflammatory condition. Interestingly, laboratory tests of COVID-19 patients revealed that sACE2 and its regulatory miRNAs were elevated and associated, demonstrating their clinical significance as biomarkers in COVID-19 disease [101].

Furthermore, Sodagar et al. showed that different kinds of miRNAs could affect the progression of various lung illnesses by targeting distinct pathways and genes. Increased levels of mir-200c are expected to contribute to reduced ACE2 production, which might increase the risk of infection, inflammation, and coronavirus illness sequelae [102].

Besides ACE2 receptors, SARS-CoV-1 entry necessitates cellular proteases to bind viral Spike protein, which leads to cleavage of Spike protein at the S1/S2 position, and the S2' position permits fusion of both viral and cellular membranes; this is process is motivated by the cleaved S2 subunit of the spike protein. The Spike protein of SARS-CoV binds to ACE2 as the entry receptor and hires the transmembrane protease serine 2 (TMPRSS2) for S protein priming [103]. Similarly, SARS-CoV-2 employs the TMPRSS2 for Spike protein priming and virus-host cell membrane fusion followed by cell entry. This is suggested as another target for antiviral development therapeutics [104]. Matarese et al. researched TMPRSS2; they found that the expression of TMPRSS2 in human endothelial cells is regulated and lowered through mir-98 by attaching to 5UTR TMPRSS2 miRNA [105].

Furthermore, because TMPRSS2 is another critical element of SARS-CoV-2 viral entry, inhibiting it could help to alleviate COVID-19 [96]. In human endothelial cells separated from the lung and the umbilical vein, miR-98-5p controls the expression of TMPRSS2, indicating that it might be used in miRNA-based COVID-19 therapies [105]. Some other report predicts that hsa-miR-32, hsa-miR-98, and hsa-miR-214 can suppress the synthesis of TMPRSS2, which might open the way for further research into the potential therapeutic effects of hsa-miR-32, hsa-miR-98, and hsa-miR-214 against SARS-CoV-2 [106]. Interestingly, hsa-miR-32 was shown to be overexpressed in Caco-2 cells, indicating that future studies must concentrate on hsa-miR-32 [106,107].

However, it would be worthwhile to investigate if miRNAs may limit the synthesis of structural and non-structural proteins involved in critical phases of the SARS-CoV-2 life cycle, including spike protein and non-structural proteins such as Nsp1, Nsp4, and Nsp12, and envelope (E) proteins [108]. Earlier studies on the SARS-CoV found that several miRNAs such as miR-17*, miR-574–5p, and miR-214 may target various proteins of the viral machinery, including S, E, and membrane (M) proteins. Additionally, ORF1a has been found to be associated with these miRNAs [72]. Interestingly as we are all aware that SARS-CoV and SARS-CoV-2 have a significant genetic similarity [109]; hence antiviral effects of such miRNAs, including miR-574–5p and miR-214, can be exploited to alleviate the COVID-19 symptoms [99].

Potential risks and side effects

Anti-inflammatory and antiviral miRNAs may be more effective when used together than when used alone. Meanwhile, targeting the viral genome, critical proteins, or miRNAs as an antiviral method for developing effective therapeutics against COVID-19 could be a promising alternative [9,110]. However, a single miRNA can affect many target miRNAs; excessive doses of a single miRNA can have substantial off-target consequences under in vivo conditions. As a result, employing a system biology approach for combinatorial therapeutics may involve a smaller dose of a cocktail of therapeutically critical microRNAs to eliminate SARS-CoV-2 without any side effects [9].

The key problems of miRNA-based therapy are targeted delivery, instability, and toxicity [9,111]; hence adequate carrier vehicles are required for successful and effective delivery of miRNAs to the sites of infection. In this context, investigations have demonstrated that mesenchymal stem cells (MSCs) have a preference for lesion or inflamed areas [9,112,113], suggesting that they could be employed to reduce the cytokine storm [9] and hence may reduce the inflammation in the lungs caused by SARS-CoV-2. Cytokine storm is an important aspect of the SARS-CoV-2 infection and has been suggested as a leading cause of death in patients with COVID-19. So, mitigating the deleterious consequences of exaggerated secretion of cytokines by miRNA therapeutics while bypassing the side effects of this approach can be a significantly efficient therapeutic regimen to treat COVID-19.

Conclusions and future prospective

Several cellular processes, including infection with RNA viruses, are regulated by miRNAs. In order to create a proviral environment that improves replication of the virus and propagation inside the host cell, RNA viruses could control the level of certain miRNAs inside the cell. Furthermore, changes in miRNA levels following viral replication are an essential component of the host response to infection, sculpting both the activation stages and the antiviral response resolution processes.

Many studies have revealed that miRNAs are involved in diverse and complex processes during the infection process of SARS-CoV-2. The virus modifies the infected host's cellular miRNAs during infection, which leads to increased viral replication and enhanced assembly of viral particles. On the other hand, cellular Non-coding RNAs, including miRNAs, act as an essential antiviral immunity component by controlling the expression of ACE2 receptors, hence reducing the viral entry into the host cell. In addition, the interaction
of cellular miRNAs with RISC proteins can cut down and silence the viral RNA. The degradation of viral RNA, along with reducing the expression of ACE2 receptors, can substantially reduce the viral load. Genetic alterations in the miRNA binding sites of the viral genome can increase pathogenicity by allowing the virus to avoid RNA degradation and silencing by cellular miRNAs. One of the hopeful methods of treating the SARS-CoV-2 infected host using non-coding RNAs (ncRNAs) is the induction of small interfering RNA (siRNA) -mediated through passing synthetic complementar siRNAs to viral RNA sequences into infected host cells.

Further refinement of this principle requires elaborate studies, which can help in the generation of potential siRNA from ncRNAs that can target the viral genomic RNA. Likewise, antiviral therapies that use miRNAs, such as vectors in vaccinations or gene therapy, have been proposed. Furthermore, the miRNAs involved in the regulation of ACE2 receptors require more attention and extensive investigations as this strategy can be employed as an effective therapeutic regime against COVID-19.

Funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement

Jivan Qasim Ahmed: Conceptualization, Data curation, Writing – original draft, Writing – review & editing. Sazan Qadir Maulud: Writing – original draft, Writing – review & editing. Manish Dhawan: Conceptualization, Data curation, Writing – original draft, Writing – review & editing. Priyanka: Writing – original draft, Writing – review & editing. Om Prakash Choudhary: Conceptualization, Supervision, Writing – original draft, Writing – review & editing. Paywast Jamal Jalal: Writing – original draft, Writing – review & editing. Rezna Kheder Ali: Writing – original draft, Writing – review & editing. Dhsad Abdulllah Hasan: Writing – original draft, Writing – review & editing. All authors critically reviewed and approved the final version of the manuscript.

Acknowledgements

All the authors acknowledge and thank their respective Universities and Institutes.

Declaration of competing interest

All authors report no conflicts of interest relevant to this article.

References

[1] Maulud SQ, Majed SQ, Ali RA, Jalal PJ, Areez SH, Mohammed KA. Epidemiological approach of SARS-CoV-2 in the first month’s appearance in the Kurdistan Region of Iraq. Eur J Mol Med 2020;7:2835–63.
[2] Choudhary OP, Priyanka, Ali RK, Maulud SQ, Dhawan M, Mohammed TA. Will the next spillover pandemic be deadlier than the COVID-19? a wake-up call. Int J Surg 2022;1062088 https://doi.org/10.1016/j.ijsu.2021.1062088.
[3] Wang H, Li X, Li T, Zhang S, Wang L, Wu X, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis 2020;39:1629–35. https://doi.org/10.1007/s10026-020-03899-4.
[4] Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470–3. https://doi.org/10.1016/S0140-6736(20)30185-9.
[5] Petrovskii N, Viceconte G, Ergonoud G, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect 2020;26:725–34. https://doi.org/10.1016/j.cmi.2020.03.026.
[6] Rabaan AA, Mutair AA, Alawi ZA, Alhumaid SA, Mollahani MA, Aldali J, et al. Comparative pathogenesis, molecular pathogenicity, immunological features, and genetic characterization of three highly pathogenic human coronaviruses (MERS-CoV, SARS-CoV, and SARS-CoV-2). Eur Rev Med Pharmacol Sci 2021;25(22):7162–84. https://doi.org/10.26355/eurrp_202111_2276.
[7] Dhawan M, Angural S, Talbot R, M. Tuberculosis during the COVID-19: impact, challenges and management. J Exp Biol Agric Sci 2020;8:79–86. https://doi.org/10.18006/2020.8.Spl–1/SARS-CoV-2/579.5.
[8] Dhawan M, Priyanka. Choudhary OP. Immunomodulatory and therapeutic implications of vitamin D in the management of COVID-19: a narrative review. Vaccine Immunother 2022;24:1–5. https://doi.org/10.26355/eurrp_202205.2025734.
[9] Arghiani N, Nissan T, Matin MM. Role of microRNAs in COVID-19 with implications for therapeutics. Biomed Pharm Rev 2021;144:112247 https://doi.org/10.1016/j.biorev.2021.03.026.
[10] Dhawan M, Dhamma K, Parmar M, Sharma A, Angural S. Unraveling the potencies of tocilizumab for the development of a potential immunomodulatory regimen against COVID-19: A narrative review. J Appl Pharm Sci 2021;11:26–33.
[11] Guterres A, de Azereido Lima CH, Miranda R, Gadellha MR. What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19? Infect Genet Evol 2020;85:104417 https://doi.org/10.1016/j.meegid.2020.104417.
[12] Rabaan AA, Al-Ahmed HM, Gourary A, Al-Quanee AM, Sole AA, Tirupathi R, et al. Diverse immunomodulatory factors influencing pathogenesis in patients with COVID-19: a review on viral dissemination, immunotherapeutic options to counter cytokine storm and inflammatory responses. J Infect Public Health 2021;10(5):565. https://doi.org/10.1016/j.jiph.2021.03.026.
[13] Girardi E, Léopold P, Pfeiffer S. On the importance of host microRNAs during viral infections. Front Genet 2018;9:439. https://doi.org/10.3389/fgen.2018.00439.
[14] Rabaan AA, Al-Ahmed HM, Muhammad J, Khan A, Sule AA, Tirupathi R, Mutair AA, Ali RK. SARS-CoV-2 RNAs: computational analysis and experimental target. J Res Sq 2020:445–6. https://doi.org/10.21203/rs.3.rs-16264/v1.
[15] Makarova JA, Shkurnikov MU, Wicklein D, Lange T, Samato TR,Turchinovich AA, et al. Intracellular and extracellular microRNA: an update on localization and biological role. Prog Histochem Cytochem 2016;51(3–4):33–49. https://doi.org/10.1016/j.prog.2016.06.001.
[16] Liu Z, Wang J, Xu Y, Guo M, Li X, Xu R, Pei Y, Zhang Q, Yuan X, Hu Z. Implications of the virus-encoded miRNA and host miRNA in the pathogenicity of SARS-CoV-2. arxiv 2020. https://doi.org/10.48550/arxiv.2004.04874.
[17] Broughton JP, Lovci MT, Huang JL, Yeo GW, Pasquinelli AE. Pairing beyond the seed supports microRNA targeting specificity. Mol Cell 2018;74(2):120–33. https://doi.org/10.1016/j.molcel.2016.09.004.
[18] Vasudevan S. Post-transcriptional upregulation by microRNAs. Wiley Inter Rev RNA 2012;3(3):311–30. https://doi.org/10.1002/wrna.121.
[19] Naharova JA, Shukurkuv MU, Wicklein D, Lange T, Samato TR, Turchinovich AA, et al. Intracellular and extracellular microRNA: an update on localization and biological role. Prog Histochem Cytochem 2016;51(3–4):33–49. https://doi.org/10.1016/j.prog.2016.06.001.
[20] Iwashchenko AT, Rakhmetullina AK, Assina DE, Akinyinayoza AV, How miRNAs can protect humans from coronaviruses COVID-19, SARS-CoV, and MERS-CoV. Res Sq 2020:445–6. https://doi.org/10.21203/rs.3.rs-16264/v1.
[21] Elsheikh E, Elsheikh M. A new approach for COVID-19 treatment by micro-RNA. Med Hypotheses 2020;143:110203 https://doi.org/10.1016/j.mehy.2020.110203.
[22] Bartoszewski R, Rabowska M, Jakieła B, Matalon S, Harrod KS, Sanak M, et al. SARS-CoV-2 may regulate cellular responses through depletion of specific host miRNAs. Am J Phsiol-Lung Cell Mol Physiol 2020;319:1444–55. https://doi.org/10.1152/ajplil.00252.2020.
[23] Lu D, Chatterjee S, Yao R, Bae C, Thum T. MicroRNAs targeting the SARS-CoV-2 receptor ACE2 in cardiomyocytes. J Mol Cell Cardiol 2020;148:46–9. https://doi.org/10.1016/j.yjmcc.2020.08.017.
[24] Lai X, Chatterjee S, Yao R, Bae C, Thum T. MicroRNAs targeting the SARS-CoV-2 receptor ACE2 in cardiomyocytes. J Mol Cell Cardiol 2020;148:46–9. https://doi.org/10.1016/j.yjmcc.2020.08.017.
[25] Lai X, Eberhardt M, Schmitz U, Vera J. Systems biology-based investigation of cooperating microRNAs as mono-therapy or adjuvant therapy in cancer. Nuclic Acid Res 2019b:47;5773–66. https://doi.org/10.1093/nar/gkz574.
[26] Marchi R, Sugita B, Cesta A, Fonseca AS, Bortolotto S, Fioreniti K, Ferreira S, Cavalli LR. The role of microRNAs in modulating SARS-CoV-2 infection in human cells: a systematic review. Infect Genet Evol 2021;91:104832 https://doi.org/10.1016/j.ijgev.2021.104832.
J.Q. Ahmed, S.Q. Maulud, M. Dhawan et al. Journal of Infection and Public Health 15 (2022) 788–799

Ahmad JQ, Tayib GA, Mohamed T. SARS-CoV-2 mutation hotspots incidence in different geographic regions. Microbial. Biosystems 2020;5:1–8.

Yu PY, Yang M, Wu LS. Annotation of microRNAs in COVID-19 coronavirus. J Electron Soc Tech Sci 2021;19:100060. https://doi.org/10.1007/100600-020-0061-1.

Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The architecture of SARS-CoV-2 transcriptome. e10 Cell 2020;181(4):941–21. https://doi.org/10.1016/j.cell.2020.09.014.

Cursons J, Pillman KA, Scheer KG, Gregory PA, Forouzan M, Hediyeh-Zadeh S, McWilliam W. The pathway of microRNA maturation. miRNA Maturat 2014:3–10.

David M. Interferons and microRNAs. J Inter Cytok Res 2010;30:825–8. https://doi.org/10.4161/jicr.30.10.10131.

Masaki T, Arend Kyle C, Li Y, Yamane D, McGiveon D, Kato T, Keyvani H, Davidsmeier H. Mili, Sani Karamposo S. The emerging role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related 2019 novel coronavirus pneumonia. Microbes 2020:1–10. https://doi.org/10.1093/microbiolsf/muaa132.

Fani M, Zandi M, Rezaei M, Khodadad N, Langari H, Amini I. The role of microRNAs in the Viral Infections. Curr Pharm Des 2018;24:4659–67. https://doi.org/10.2174/1381612824666180426201910.

Dickey LW, Worne CL, Glover JL, Lane TE, O’Connell RM. MicroRNA-155 enhances T cell trafficking and antiviral effector function in a model of coronavirus-induced neurologic disease. J Neurolimmun 2016:13-24. https://doi.org/10.1016/j.jninf.2016.01.002.

Chow JTS, Salmena L. Prediction and analysis of SARS-CoV-2-targeting microRNA in human lung epithelium. Genes 2020;11:1002. https://doi.org/10.3390/genes11091002.

Sanam M, Mahmoudi S, Mohammad M, Khabadjahjibaji A. Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors. Inf Med Uncovered 2020:1000470. https://doi.org/10.2174/1874213X1000470.

Chau AP, Choi Y, Schork NJ. Conserved terminal sites of SARS-CoV-2 as coevolving functional elements and potential therapeutic targets. e00754-20. MSphere 2020;5. https://doi.org/10.1128/mSphere.00754-20.

Hudson BS, Kolte V, Khan A, Sharma G. Dynamic tracking of variant frequencies depicts the evolution of mutation sites amongst SARS-CoV-2 genomes from India. J Med Virol 2020:33-2534-7. https://doi.org/10.1002/jmv.27656.

Mukhopadhyay D, Mussa BM. Identification of novel hypalathmic microRNAs as promising therapeutic agents for SARS-CoV-2 by regulating ACE2 and TMPRSS2 expression: an in silico analysis. Brain Sci 2020;10:666. https://doi.org/10.3390/brainsci10040666.

Abu-Izaid T, Alhajji N, Ibrahim AM, Javed MN, Salem KM, Pottoo FH, Kamal MA. Micro-RNAs in the regulation of immune response against SARS-CoV-2 and other viral infections. J Adv Res 2021;30:113–45. https://doi.org/10.1016/j.jare.2021.09.013.

Arasan ED, Dart A, Grant GH, Arisan S, Cuhadaroglu S, Lange S, Uysal-Onogar P. The prediction of microRNAs in SARS-CoV-2 genomes: hsa-miR databases identify 7 unique miRs linked to viral genes and viral infection/biogenesis related KEGG pathways significant for comorbidity. Viruses 2020;12:814. https://doi.org/10.3390/v12040814.

Xu J, Zhao S, Teng T, Abdulai AE, Zha W, Xie L, et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV and SARS-CoV-2. Viruses 2020;12:244. https://doi.org/10.3390/v12030244.

Millicic B, Ghosh Z, Kacharkarji J, MicroRNA analysis unravels the molecular basis of SARS infection in bronchoalveolar stem cells. PLoS One 2020;7:77837. https://doi.org/10.1371/journal.pone.027837.

Rad Sm AH, McLellan AD. Implications of SARS-CoV-2 mutations for genetic RNA structure and host microRNA targeting. Int J Mol Sci 2021;20:4807. https://doi.org/10.3390/ijms202104807.

Fulzele S, Sahay B, Yousufu I, Lee TJ, Sharma A, Kolhe R, Isales CM. COVID-19 virulence in aged patients might be impacted by the host cellular microRNAs abundance/profile. Aging Dis 2020;11:509–22. https://doi.org/10.1007/13816-020-00428.

Gutmann C, Haminia K, Theofiliatos K, Dienderfer AB, Burnap SA, Adam Nabbebacceus A, et al. Association of cardiotrophin microRNAs with COVID-19 severity and mortality. Cardiovasc Res 2022;118(2):461–74. https://doi.org/10.1093/cvr/cvabar338.

Guo XQ, Zhang Q, Gao L, Li XN, Chen XF, Feng WH. Increasing expression of microRNA-181 inhibits the reproductive and respiratory virus replication and has implications for controlling virus infection. J Virol 2013;87:1159–71. https://doi.org/10.1128/JVI.00718-13.

Li L, Gao F, Jiang Y, Li Z, Zhou Y, Zheng H, Tong W, Yang S, Xia T, Qu Z, Tong G. COVID-19: A mathematical model of reproductive and respiratory virus in vitro and in vivo. Sci Rep 2020;5:17100. https://doi.org/10.1038/s41598-020-71070-4.

Fulzele S, Sahay B, Yousufu I, Lee TJ, Sharma A, Kolhe R, Isales CM. COVID-19 virulence in aged patients might be impacted by the host cellular microRNAs abundance/profile. Aging Dis 2020;11:509–22. https://doi.org/10.1007/13816-020-00428.

Fulzele S, Sahay B, Yousufu I, Lee TJ, Sharma A, Kolhe R, Isales CM. COVID-19 virulence in aged patients might be impacted by the host cellular microRNAs abundance/profile. Aging Dis 2020;11:509–22. https://doi.org/10.1007/13816-020-00428.

Fulzele S, Sahay B, Yousufu I, Lee TJ, Sharma A, Kolhe R, Isales CM. COVID-19 virulence in aged patients might be impacted by the host cellular microRNAs abundance/profile. Aging Dis 2020;11:509–22. https://doi.org/10.1007/13816-020-00428.

Fulzele S, Sahay B, Yousufu I, Lee TJ, Sharma A, Kolhe R, Isales CM. COVID-19 virulence in aged patients might be impacted by the host cellular microRNAs abundance/profile. Aging Dis 2020;11:509–22. https://doi.org/10.1007/13816-020-00428.

Fulzele S, Sahay B, Yousufu I, Lee TJ, Sharma A, Kolhe R, Isales CM. COVID-19 virulence in aged patients might be impacted by the host cellular microRNAs abundance/profile. Aging Dis 2020;11:509–22. https://doi.org/10.1007/13816-020-00428.

Fulzele S, Sahay B, Yousufu I, Lee TJ, Sharma A, Kolhe R, Isales CM. COVID-19 virulence in aged patients might be impacted by the host cellular microRNAs abundance/profile. Aging Dis 2020;11:509–22. https://doi.org/10.1007/13816-020-00428.
Rizkita LD, Astolfi P. The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review. J Pharm Anal 2021;11:265–71. https://doi.org/10.1016/j.jpha.2021.03.003

Narouma M, Rubi S. Anti-SARS-CoV-2 strategies and the potential role of miRNA in the assessment of COVID-19 morbidity, recurrence, and therapy. Int J Mol Sci 2021;22: https://doi.org/10.3390/ijms22168663

Fani M, Zandi M, Ebrahimi S, Soltani S, Abbasi S. The role of miRNAs in COVID-19 disease. Future Virol 2021;16:301–308. https://doi.org/10.2217/fvl-2020-0393.

Widiastina A, Sribudijana Y, Nugrahaprjha H, Hilmanto D, Sekarwana N, Rachmadi D. Potential role of ACE2-related microRNAs in COVID-19-associated nephropathy. Non-coding RNA Res 2020;5:153–66. https://doi.org/10.1016/j.jnrcr.2020.09.001.

Roganovic J. Downregulation of microRNA-146a in diabetes, obesity and hypertension may contribute to severe COVID-19. Med Hypotheses 2021;146:110448 https://doi.org/10.1016/j.mehy.2020.110448

Haddad H, Walid AZ. miRNA target prediction might explain the reduced transmission of SARS-CoV-2 in Jordan, Middle East. Non-coding RNA Res 2020;5:135–43. https://doi.org/10.1016/j.jnrcr.2020.08.002.

Farr RJ, Rootes CL, Rowntree LC, Nguyen THO, Hensen L, Kedzierski L, Cheng AC, Kedzierska K, Au GG, Marsh GA, Vasan SS, Foo CH, Cowled C, Stewart CR. Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection. PLoS Pathog 2021;17:e1009759 https://doi.org/10.1371/journal.ppat.1009759.

Centa A, Fonseca AS, Ferreira S, Azevedo MLV, Vaz De Paula CB, Nagashima S, Machado-Souza C, Miggiolaro A, Baena CP, De Noronha L, Cavalli LR. Deregulated miRNA expression is associated with endothelial dysfunction in post-mortem lung biopsies of COVID-19 patients. Am J Physiol Lung Cell Mol Physiol 2020;320:L405–12. https://doi.org/10.1152/ajplung.00257.2019.

Sardar R, Kapila S, Kapila R, Kumar S, Upadhyay D, Kaur M, et al. Tmprss2 specific microRNAs as promising regulators for SARS-CoV-2 entry checkpoint. Virus Res 2021;294:198275 https://doi.org/10.1016/j.virusres.2020.104792.

Li C, Wang R, Wu A, et al. SARS-COV-2 as potential microRNA sponge in COVID-19 patients. BMC Med Genom 2022;15:94. https://doi.org/10.1186/s12920-022-01243-7.

Yadav R, Chaudhary JK, Jain N, Chaudary PK, Khanna S, Dhampi P, et al. Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells 2021;10:41. https://doi.org/10.3390/Cells1004041.

Chen Z, Boon SS, Wang MH, Chan RWY, Chan PKS. Genomic and evolutionary comparison between SARS-CoV-2 and other human coronaviruses. J Virol Methods 2021;289:114032 https://doi.org/10.1016/j.jviromet.2020.114032.

Rabaan AA, Al Mutair A, Alhumaid S, Al Ala wii Z, Al Mohaini R, Alsalman AJ, et al. Modulation of host epigenome by coronavirus infections and developing treatment modalities for COVID-19 beyond genetics. Eur Rev Med Pharm Sci 2021;25(19):5947–64. https://doi.org/10.2671/eurev.202110.26872.

Höbel S, Aigner A. Poly ethylenimines for siRNA and miRNA delivery in vivo. Wiley interdisciplinary reviews. Nanomed Nanobiotechnology 2013;5:484–501. https://doi.org/10.1002/wnan.1228.

Chen Y, He Y, Wang X, Lu F, Gao J. Adipose-derived mesenchymal stem cells exhibit tumor tropism and promote tumour formation of breast cancer cells. Oncol Rep 2019;41:2126–36. https://doi.org/10.3892/or.2019.7018.

Loftingeg P, Samsasenjan K, Movassaghpoor A, Majidi J, Baradanar B. Immunomodulatory nature and site specific affinity of mesenchymal stem cells: a hope in cell therapy. Adv Pharm Bull 2014;4:5–13. https://doi.org/10.5681/apb.2014.002.